Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.
AIMS: Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder, associated with alterations of bowel function, abdominal pain and other symptoms related to the GI tract. Recently the endogenous cannabinoid system (ECS) was shown to be involved in the physiological and pathophysi...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3874007?pdf=render |
| _version_ | 1819128970154606592 |
|---|---|
| author | Jakub Fichna Jodianne T Wood Malvina Papanastasiou Subramanian K Vadivel Piotr Oprocha Maciej Sałaga Marta Sobczak Anna Mokrowiecka Adam I Cygankiewicz Piotr K Zakrzewski Ewa Małecka-Panas Wanda M Krajewska Piotr Kościelniak Alexandros Makriyannis Martin A Storr |
| author_facet | Jakub Fichna Jodianne T Wood Malvina Papanastasiou Subramanian K Vadivel Piotr Oprocha Maciej Sałaga Marta Sobczak Anna Mokrowiecka Adam I Cygankiewicz Piotr K Zakrzewski Ewa Małecka-Panas Wanda M Krajewska Piotr Kościelniak Alexandros Makriyannis Martin A Storr |
| author_sort | Jakub Fichna |
| collection | DOAJ |
| description | AIMS: Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder, associated with alterations of bowel function, abdominal pain and other symptoms related to the GI tract. Recently the endogenous cannabinoid system (ECS) was shown to be involved in the physiological and pathophysiological control of the GI function. The aim of this pilot study was to investigate whether IBS defining symptoms correlate with changes in endocannabinoids or cannabinoid like fatty acid levels in IBS patients. METHODS: AEA, 2-AG, OEA and PEA plasma levels were determined in diarrhoea-predominant (IBS-D) and constipation-predominant (IBS-C) patients and were compared to healthy subjects, following the establishment of correlations between biolipid contents and disease symptoms. FAAH mRNA levels were evaluated in colonic biopsies from IBS-D and IBS-C patients and matched controls. RESULTS: Patients with IBS-D had higher levels of 2AG and lower levels of OEA and PEA. In contrast, patients with IBS-C had higher levels of OEA. Multivariate analysis found that lower PEA levels are associated with cramping abdominal pain. FAAH mRNA levels were lower in patients with IBS-C. CONCLUSION: IBS subtypes and their symptoms show distinct alterations of endocannabinoid and endocannabinoid-like fatty acid levels. These changes may partially result from reduced FAAH expression. The here reported changes support the notion that the ECS is involved in the pathophysiology of IBS and the development of IBS symptoms. |
| first_indexed | 2024-12-22T08:36:17Z |
| format | Article |
| id | doaj.art-41cbd30d09b1462080790b70223e7a13 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T08:36:17Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-41cbd30d09b1462080790b70223e7a132022-12-21T18:32:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8507310.1371/journal.pone.0085073Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.Jakub FichnaJodianne T WoodMalvina PapanastasiouSubramanian K VadivelPiotr OprochaMaciej SałagaMarta SobczakAnna MokrowieckaAdam I CygankiewiczPiotr K ZakrzewskiEwa Małecka-PanasWanda M KrajewskaPiotr KościelniakAlexandros MakriyannisMartin A StorrAIMS: Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder, associated with alterations of bowel function, abdominal pain and other symptoms related to the GI tract. Recently the endogenous cannabinoid system (ECS) was shown to be involved in the physiological and pathophysiological control of the GI function. The aim of this pilot study was to investigate whether IBS defining symptoms correlate with changes in endocannabinoids or cannabinoid like fatty acid levels in IBS patients. METHODS: AEA, 2-AG, OEA and PEA plasma levels were determined in diarrhoea-predominant (IBS-D) and constipation-predominant (IBS-C) patients and were compared to healthy subjects, following the establishment of correlations between biolipid contents and disease symptoms. FAAH mRNA levels were evaluated in colonic biopsies from IBS-D and IBS-C patients and matched controls. RESULTS: Patients with IBS-D had higher levels of 2AG and lower levels of OEA and PEA. In contrast, patients with IBS-C had higher levels of OEA. Multivariate analysis found that lower PEA levels are associated with cramping abdominal pain. FAAH mRNA levels were lower in patients with IBS-C. CONCLUSION: IBS subtypes and their symptoms show distinct alterations of endocannabinoid and endocannabinoid-like fatty acid levels. These changes may partially result from reduced FAAH expression. The here reported changes support the notion that the ECS is involved in the pathophysiology of IBS and the development of IBS symptoms.http://europepmc.org/articles/PMC3874007?pdf=render |
| spellingShingle | Jakub Fichna Jodianne T Wood Malvina Papanastasiou Subramanian K Vadivel Piotr Oprocha Maciej Sałaga Marta Sobczak Anna Mokrowiecka Adam I Cygankiewicz Piotr K Zakrzewski Ewa Małecka-Panas Wanda M Krajewska Piotr Kościelniak Alexandros Makriyannis Martin A Storr Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. PLoS ONE |
| title | Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. |
| title_full | Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. |
| title_fullStr | Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. |
| title_full_unstemmed | Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. |
| title_short | Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. |
| title_sort | endocannabinoid and cannabinoid like fatty acid amide levels correlate with pain related symptoms in patients with ibs d and ibs c a pilot study |
| url | http://europepmc.org/articles/PMC3874007?pdf=render |
| work_keys_str_mv | AT jakubfichna endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT jodiannetwood endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT malvinapapanastasiou endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT subramaniankvadivel endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT piotroprocha endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT maciejsałaga endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT martasobczak endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT annamokrowiecka endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT adamicygankiewicz endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT piotrkzakrzewski endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT ewamałeckapanas endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT wandamkrajewska endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT piotrkoscielniak endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT alexandrosmakriyannis endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy AT martinastorr endocannabinoidandcannabinoidlikefattyacidamidelevelscorrelatewithpainrelatedsymptomsinpatientswithibsdandibscapilotstudy |